PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here.

SHARE